AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.270

-0.090-0.59%

Volume:1.64M

Turnover:24.72M

Market Cap:5.17B

PE:114.41

High:15.300

Open:15.220

Low:14.860

Close:15.360

52wk High:18.320

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:1.40

T/O Rate:0.59%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.133

EPS(LYR):-0.030

ROE:7.36%

ROA:2.71%

PB:7.58

PE(LYR):-517.21

Loading ...

Overview Company News Filings

Telix Pharmaceuticals Ltd - Q1 2026 Unaudited Group Revenue of US$230 Mln

THOMSON REUTERS

Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?

Simply Wall St.

Telix Appoints David Gill as Non-Executive Director

Telix Pharmaceuticals Ltd - David Gill Is Expected to Be Appointed as Chair in Due Course

THOMSON REUTERS

Telix files Form 3 for Group CFO Darren Charlton Smith initial beneficial ownership statement

Telix files initial beneficial ownership statement for Group COO Darren Patti

Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?

Simply Wall St.

Thor Medical FY2025 annual report published; operating profit (EBIT) falls to NOK -70 million

Stock Track | Telix Pharmaceuticals Soars 5.03% Intraday on FDA Submission Progress and Growth Outlook

ASX Biggest Gainers

MT Newswires Live

ASX Growth Companies With Insider Ownership Up To 38%

Simply Wall St.

Heidelberg Pharma FY2025 annual report published; net loss widens to EUR -42 million

How I'd invest $20,000 in ASX shares right now to help build long-term wealth

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates

Simply Wall St.

3 top ASX shares that could double in value from here

These are the 10 most shorted ASX shares

Bell Potter says these ASX 200 stocks could rise 50%+

Telix Pharmaceuticals (ASX:TLX) Is Up 12.9% After TLX101-Px NDA Resubmission and U.S. Build-Out News – Has The Bull Case Changed?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/TLX.AU/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.27,"timestamp":1788243120000,"preClose":15.36,"halted":0,"volume":1638595,"delay":0,"changeRate":-0.005859374999999991,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.1334700879576639,"marketStatus":"Not Yet Opened","change":-0.09,"latestTime":"09-01 16:12:00 AEST","open":15.22,"high":15.3,"low":14.86,"amount":24723649,"amplitude":0.028646,"askPrice":15.29,"askSize":1000,"bidPrice":15.22,"bidSize":300,"shortable":3,"etf":0,"ttmEps":0.1334700879576639,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":15.36,"openAndCloseTimeList":[[1788220800000,1788242400000]],"volumeRatio":1.3998626960176648,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":15.36,"auctionPrice":15.26,"auctionVolume":248669,"auction":3,"marketStatus":"盘后竞价","timestamp":1788243005736}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029524,"volumeRatio":1.3998626960176648,"shares":338721355,"dividePrice":0,"high":15.3,"amplitude":0.028646,"preClose":15.36,"low":14.86,"week52Low":8.26,"pbRate":"7.58","psRate":"4.15","week52High":18.32,"institutionHeld":0,"latestPrice":15.27,"committee":-0.538462,"eps":0.1334700879576639,"divideRate":0,"volume":1638595,"delay":0,"ttmEps":0.1334700879576639,"open":15.22,"prevYearClose":11.2,"prevWeekClose":15.65,"prevMonthClose":15.36,"prevQuarterClose":16.58,"fiveDayClose":16.16,"twentyDayClose":14.41,"sixtyDayClose":13.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625075516","title":"Telix Pharmaceuticals Ltd -  Q1 2026 Unaudited Group Revenue of US$230 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2625075516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625075516?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:29","pubTimestamp":1775514540,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625233628","title":"Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625233628","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625233628?lang=en_us&edition=fundamental","pubTime":"2026-04-06 04:12","pubTimestamp":1775419922,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently announced that David Gill will join its Board as a Non-Executive Director on 11 May 2026, with plans for him to succeed Dr. Mark Nelson as Chair while Nelson remains a Non-Executive Director.\nThe appointment brings a veteran life sciences executive with extensive radiopharmaceutical, capital markets and governance experience onto Telix’s Board, potentially reshaping how the company balances growth ambitions with oversight as a dual-listed business.\nWe’ll now...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/will-telix-asxtlx-board-refresh-subtly-recast-its-governance","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/will-telix-asxtlx-board-refresh-subtly-recast-its-governance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","BK4139","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624547779","title":"Telix Appoints David Gill as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2624547779","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624547779?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:59","pubTimestamp":1775084340,"startTime":"0","endTime":"0","summary":"Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoiceHoldings, Inc. , INC Research , and CTI Molecular Imaging . He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.Telix Interim Chair, Mark Nelson, commented, \"We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.\". Telix Investor Relations Ms. Charlene JawAssociate Director Investor Relations[emailprotected]","market":"us","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-appoints-david-gill-as-non-executive-director-302732101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","BK7067","TQQQ","QYLG","NQmain","YMAB","BK4139","INCR","NDX","QLD","QQQE","QQQY","BK4007","TLX","TLX.AU","EOLS","BK4526","QQQ","SBBP","QDTE","ASX","MNQmain","JEPQ","SQQQ","NVIW.SI","QID","FTEC","BK4141","BK7039","ASX.AU","PSQ","QQQJ","QQQM","SEC.AU","IYW",".IXIC","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624547470","title":"Telix Pharmaceuticals Ltd -  David Gill Is Expected to Be Appointed as Chair in Due Course","url":"https://stock-news.laohu8.com/highlight/detail?id=2624547470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624547470?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:52","pubTimestamp":1775083928,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUE6CBBLS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624494590","title":"Telix files Form 3 for Group CFO Darren Charlton Smith initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624494590","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624494590?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:25","pubTimestamp":1775042743,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Group Chief Financial Officer Darren Charlton Smith reported direct ownership of 10,810 ordinary shares in an initial Form 3 filing dated April 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDLbBgcMn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590122","title":"Telix files initial beneficial ownership statement for Group COO Darren Patti","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590122","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590122?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:24","pubTimestamp":1775042681,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Group Chief Operating Officer Darren Patti filed an initial U.S. insider ownership report dated March 18, 2026, showing 25,558 ordinary shares held.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL7CrF77:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622809302","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622809302","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622809302?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:14","pubTimestamp":1774653245,"startTime":"0","endTime":"0","summary":"In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara, 18F-FET), an investigational PET imaging agent for distinguishing recurrent or progressive glioma from treatment effects in adult and pediatric patients, incorporating additional data and analysis requested after a prior Complete Response Letter.\nThe filing is significant because TLX101-Px holds both Orphan Drug and Fast Track designations and could become the first FDA-approved...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-71-after-resubmitting-tlx","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-71-after-resubmitting-tlx","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","LABU","TLX","BK7067","BK4139","BK4585","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622279848","title":"Thor Medical FY2025 annual report published; operating profit (EBIT) falls to NOK -70 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622279848","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622279848?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:04","pubTimestamp":1774595045,"startTime":"0","endTime":"0","summary":"Thor Medical reported progress on building AlphaOne at Herya Industrial Park, following a final investment decision in March 2025.Capacity at the AlphaOne plant was expanded by about 40%, with the company targeting full operational status by the end of Q3 2026.Commercial activity included multi-year supply agreements with AdvanCell, Oncoinvent, Telix Pharmaceuticals, NucliThera, and RadioMedix, and an order backlog of about NOK 850 million.Operations included continued pilot-plant output of thorium-228, radium-224, and lead-212, and first revenue from initial lead-212 deliveries.Funding for AlphaOne was described as completed, including about NOK 300 million in total equity raised since December 2024 and a NOK 90 million loan commitment from Innovation Norway.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDLWBYvP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196980695","title":"Stock Track | Telix Pharmaceuticals Soars 5.03% Intraday on FDA Submission Progress and Growth Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1196980695","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196980695?lang=en_us&edition=fundamental","pubTime":"2026-03-27 13:04","pubTimestamp":1774587878,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Limited (ASX:TLX) experienced a significant intraday surge, with its stock price soaring 5.03% on Friday. The movement highlights strong investor interest in the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622815251","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2622815251","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622815251?lang=en_us&edition=fundamental","pubTime":"2026-03-27 09:54","pubTimestamp":1774576443,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest gains on Friday.Whitehaven Coal : +3%, AU$9.13New Hope : +3%, AU$5.63Telix Pharmaceuticals : +2%, AU$13.29Yancoal Australia : +2%, AU$8.284D Medical : +3%, AU$6.48a2 Milk : +2%, AU$9.43Life360 : +1%, AU$19.25News : +1%, AU$39.98Ampol : +1%, AU$33.57Harvey Norman Holdings : +1%, AU$5.05","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WHC.AU","BK7505","BK7153","BK7141","TLX.AU","A2M.AU","BK7016","HVN.AU","NWS.AU","BK7083","NHC.AU","ALD.AU","BK7038","BK7507","BK7067","360.AU","4DX.AU","BK7065","BK7509","BK7094","YAL.AU","BK7041"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622895939","title":"ASX Growth Companies With Insider Ownership Up To 38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895939?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:08","pubTimestamp":1774552107,"startTime":"0","endTime":"0","summary":"As the Australian stock market experiences a modest rise amidst geopolitical uncertainties, investors are keeping a close watch on sectors poised for growth and resilience. In such an environment, companies with high insider ownership often attract attention due to the confidence they signal in their own potential, making them intriguing prospects for those seeking long-term growth opportunities.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4108","AEM.AU","TOR.AU","FEX.AU","BK4505","REG.AU","BK7017","BK7007","BK7113","AV1.AU","BK7110","BK7067","CUV.AU","TLX","BK4139","BK7104","BK4531","IQ","BK7129","BK4552","AR1.AU","FRS.AU","CYC.AU","BK7095","EIQ.AU","BK7016","BK4526","TLX.AU","BK7508","MAU.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622836040","title":"Heidelberg Pharma FY2025 annual report published; net loss widens to EUR -42 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622836040","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622836040?lang=en_us&edition=fundamental","pubTime":"2026-03-26 14:53","pubTimestamp":1774508032,"startTime":"0","endTime":"0","summary":"Heidelberg Pharma’s annual report outlines a strategic refocus on its lead Amanitin-based ADC program HDP-101 after a delayed milestone tied to Telix’s TLX250-Px, which received an FDA Complete Response Letter citing CMC comparability and third-party manufacturing deficiencies.Clinical updates include continued dose escalation for HDP-101 in relapsed or refractory multiple myeloma, with an objective response rate of 57% reported in cohort 8 at 140 g/kg and Fast Track designation granted by the FDA.Business development highlights include a March 2025 amendment to the HealthCare Royalty agreement that provided an upfront payment of USD 20 million and the start of clinical development by partner Takeda for an ATAC candidate after the reporting period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL6QP1pl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622001389","title":"How I'd invest $20,000 in ASX shares right now to help build long-term wealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001389","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622001389?lang=en_us&edition=fundamental","pubTime":"2026-03-26 03:15","pubTimestamp":1774466100,"startTime":"0","endTime":"0","summary":"Putting $20,000 to work in the market is a meaningful step. At that size, I'd be thinking about building a portfolio that can grow through different conditions.For me, that means combining quality, growth, and a bit of resilience.Here's why I would split the money across these four names.Hub24 continues to build momentum in a way that's hard to ignore.It operates a wealth management platform that continues to attract funds from advisers and clients moving toward more sophisticated investment solutions.What stands out to me is its ability to consistently grow funds under administration. That kind of growth can compound over time, especially as the shift toward managed platforms continues.It's an ASX share that I think could look significantly larger in a decade than it does today.James Hardie Industries brings exposure to global construction and housing.That might sound cyclical, and it is, but James Hardie has built a strong position in fibre cement products, particularly in the United","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/26/how-id-invest-20000-in-asx-shares-right-now-to-help-build-long-term-wealth-2/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/26/how-id-invest-20000-in-asx-shares-right-now-to-help-build-long-term-wealth-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7507","BK7511","BHP.AU","BK7044","HUB.AU","BK7067","JHX.AU","BK7095","TLX.AU","BK7054"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621507720","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621507720","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621507720?lang=en_us&edition=fundamental","pubTime":"2026-03-23 12:27","pubTimestamp":1774240038,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has entered a busy regulatory phase, resubmitting its TLX101-Px New Drug Application for glioma imaging while also reporting that the lead-in stage of its TLX591-Tx Phase 3 prostate cancer trial met safety objectives.\nSee our latest analysis for Telix Pharmaceuticals.\nThese regulatory updates come after a strong short term run, with a 1 month share price return of 22.24% and a 7 day share price return of 12.93%. However, the 1 year total shareholder return is...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-key-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-key-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK7067","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621744550","title":"3 top ASX shares that could double in value from here","url":"https://stock-news.laohu8.com/highlight/detail?id=2621744550","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621744550?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:27","pubTimestamp":1774218446,"startTime":"0","endTime":"0","summary":"It's been a rough stretch for some of the most talked-about ASX shares. But here's the twist: while share prices have slid or stalled, broker optimism hasn't. In fact, it's surging.Three ASX shares stand out right now: Mesoblast Ltd , Telix Pharmaceuticals Ltd , and Zip Co Ltd . All three have had turbulent months. Yet analysts see massive upside, in some cases, more than a double from here.This ASX share has had a shaky start to the year, with the share price down about 25%. That's nothing new for this high-risk biotech stock. Volatility comes with the territory.Analyst outlook: This is where things get interesting. Brokers have an average price target on the ASX share of $4.23 at the time of writing. That implies around 105% upside. In other words, analysts believe a doubling is firmly on the table if execution improves.Analyst outlook: Despite all that, brokers are highly optimistic. The average price target is $4.21. That's about 191% upside — nearly triple its current share price.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/23/3-top-asx-shares-that-could-double-in-value-from-here/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/23/3-top-asx-shares-that-could-double-in-value-from-here/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MSB.AU","BK7501","ZIP.AU","BK7508","BK7093","BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621774129","title":"These are the 10 most shorted ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621774129","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621774129?lang=en_us&edition=fundamental","pubTime":"2026-03-23 05:54","pubTimestamp":1774216455,"startTime":"0","endTime":"0","summary":"At the start of each week, I like to look atASIC's short position reportto find out which shares are being targeted by short sellers.This is because I believe it is well worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn't quite right with a company.With that in mind, here are the 10 most shorted shares on the ASX this week according to ASIC:. Domino's Pizza Enterprises Ltd  continues to be the most shorted ASX share with short interest of 16%. This is up week on week. Short sellers appear doubtful that the struggling pizza chain operator's turnaround strategy will be a success.Treasury Wine Estates Ltd  has seen its short interest rise again to 15.1%. This wine giant has been battling very tough trading conditions, with consumers focusing on value rather than its premium wines.Flight Centre Travel Group Ltd  has short interest of 10.3%, which is up week on week. There are concerns that the travel agent won't deliver on its reve","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/23/these-are-the-10-most-shorted-asx-shares-23-march-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/23/these-are-the-10-most-shorted-asx-shares-23-march-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["PNV.AU","BK7095","BK7508","BK7132","TLX.AU","BOE.AU","TWE.AU","BK7083","BK7126","GYG.AU","BK7097","BK7067","BK7503","BK7070","BK7137","DMP.AU","BK7505","NAN.AU","LYC.AU","FLT.AU","BK7507","IEL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621792517","title":"Bell Potter says these ASX 200 stocks could rise 50%+","url":"https://stock-news.laohu8.com/highlight/detail?id=2621792517","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621792517?lang=en_us&edition=fundamental","pubTime":"2026-03-22 06:33","pubTimestamp":1774132380,"startTime":"0","endTime":"0","summary":"If you are looking to add some ASX 200 stocks to your portfolio this week, it could be worth checking out the two in this article. That's because Bell Potter believes they could be dirt cheap at curre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/22/bell-potter-says-these-asx-200-stocks-could-rise-50/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/22/bell-potter-says-these-asx-200-stocks-could-rise-50/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BLA.AU","BK7094","BK7067","TLX.AU","PME.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621183756","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 12.9% After TLX101-Px NDA Resubmission and U.S. Build-Out News – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621183756","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621183756?lang=en_us&edition=fundamental","pubTime":"2026-03-21 01:13","pubTimestamp":1774026782,"startTime":"0","endTime":"0","summary":"In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara), an investigational PET imaging agent for distinguishing recurrent or progressive glioma from treatment-related changes in adults and children, incorporating additional data requested after a prior Complete Response Letter and supported by Orphan Drug and Fast Track designations.\nA key differentiator is that 18F-FET imaging like TLX101-Px is already referenced in international glioma...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-129-after-tlx101-px-nda-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-129-after-tlx101-px-nda-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BGSX","BK7067","TLX.AU","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":198,"code":"91000000","status":"200"}]}}